Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $49 PT on CVS Caremark Corporation

Related CVS
Pharmacy Stocks Follow Walgreen Company's Lead Amid Earnings Release
Can Wal-Mart Stores, Inc. Compete With Other Health Care Clinics?
Home Depot Investigates Potential Hacking, CVS Says Farewell to Tobacco Products (Fox Business)

In a report published Friday, Bank of America Merrill Lynch reiterated its Buy rating and $49.00 price target on CVS Caremark Corporation (NYSE: CVS).

BofA Merrill Lynch noted, “According to media reports, CVS will buy an 80% stake in Brazilian retail pharmacy chain Onofre for $313 million, plus assumed debt. The deal adds 44 stores (the eighth-largest chain in Brazil) in a high-growth region with rapidly expanding health care coverage. However, we maintain our 2013 EPS estimate ($3.57) at this time, on the relatively small investment size and what we expect are few operating synergies.”

CVS Caremark Corporation closed on Thursday at $46.71.

Latest Ratings for CVS

DateFirmActionFromTo
Sep 2014Cowen & CompanyUpgradesMarket PerformOutperform
Aug 2014BarclaysMaintainsOverweight
Aug 2014JP MorganMaintainsOverweight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters